Comparison of transcript levels found that in this patient cohort NAA40 was the NAT enzyme with the greatest differential expression between non-tumour and tumour samples (2.1 Fold change, p<0.001 Table 2), with NAA10 and NAA20 also upregulated more than 1.5-fold in tumour samples. This evidence concerns the gene BRD2 and neoplasm.